Kohei shitara
@KoheiShitara
Medical oncologist at National Cancer Center Hospital East, Japan #gicancers #gastriccancer #colorectalcancer
DG04 officially published @NEJM @ASCO. This comes 10 years after my first phase 1 patient. DG04 took 3.5+ years due to <15% HER2+ and fresh biopsy to confirm HER2. Grateful for global effort—hoping this expands T-DXd access worldwide nejm.org/doi/full/10.10… @OncoAlert @oncodaily
Happy to share initial report on temporal change of CLDN18.2 after chemo + zolbetuximab: ~50% showed decreased expression (<75%+ cells) on PD, but 75% retained ≥25% expression—supporting potential for other CLDN-targeted tx like ADCs @ESMO_Open @myESMO sciencedirect.com/science/articl…
It’s my great honor to write the editorial for the pivotal MATTERHORN study @NEJM @YJanjigianMD @ASCO More global collaboration is needed to further improve outcomes for our patients with gastric/GEJ cancer.@OncoAlert @oncodaily nejm.org/doi/full/10.10…
A novel gut bacterium, Hominenteromicrobium mutabilis YB328, boosts anti‑PD‑1 by activating CD103⁺CD11b⁻ dendritic cells → tumor-targeting CD8⁺ T cells migrate into tumors. Gut microbes could be next-gen immunotherapy adjuvants?@Nature nature.com/articles/s4158…
FORTITUDE 101 is a positive Phase 3 study in FGFR2b overexpresssed gastroesophageal cancers! Looking forward to seeing the data and also for FORTITUDE 102 results with combines IO. #FGFR2b amgen.com/newsroom/press….
The @OncoAlert @VJOncology JOURNAL CLUB This week we have the pleasure to bring you our OncoAlert Colleague @KoheiShitara 🇯🇵Discussing his paper: Trastuzumab Durextecan or Ramucirumab plus paclitaxel in gastric cancer out on NEJM nejm.org/doi/10.1056/NE… #OncoAlertAF…
Clinical characterization of FGFR2b expression in patients with advanced gastric or gastroesophageal junction adenocarcinoma in @ESMO_Open. 30% prevalence of FGFR2b protein expression, 53.9% of them negative for currently actionable biomarkers. esmoopen.com/article/S2059-…
CLDN18 Expression and Isoform Distribution mainly in GI cancers. Trend of reduced overall CLDN18 expression after chemo with decrease CLDN18.2/18.1 proportion. Need similar analysis of isoform switch after chemo+Zolbe @OncoAlert onlinelibrary.wiley.com/doi/10.1111/ca…
Pleased to report FGFR2b expression in gastric cancer and relationship with other biomarkers @ESMO_Open @myESMO. The results of bemarituzumab phase 3 studies are awaited.@OncoAlert @oncodaily sciencedirect.com/science/articl…
🚨 Late-breaking from #ASCO25: Dr. Kohei Shitara (@KoheiShitara) presents LBA4002 – DESTINY-Gastric04! T-DXd challenges RAM+PTX in 2L HER2+ metastatic #gastriccancer & GEJA 🔬 Will this redefine the standard of care?tinyurl.com/3zm6wkeb #HER2Positive #ASCO2025 #ASCO25
A tribute to Dr. Agatsuma was a meaningful moment during my DESTINY-Gastric04 presentation at #ASCO25 with @NEJM publication. I deeply respect him and the entire team behind the development of T-DXd. @ASCO @OncoAlert @DaiichiSankyo @DaiichiSankyoUS @AstraZeneca @Oncology_at_AZ
エンハーツが胃癌の標準治療をまた塗り替えました。NEJMへ同時掲載。 今回も、 @KoheiShitara 先生が筆頭。同じ日本人として誇りに思います。 #ASCO25 nejm.org/doi/full/10.10…
Presented at #ASCO25: In HER2-positive metastatic gastric cancer, trastuzumab deruxtecan led to longer survival and better response than ramucirumab–paclitaxel. Adverse events were common. Lung toxic effects with T-DXd were mainly low grade. Full DESTINY-Gastric04 trial:…
Thrilled to share our latest Review on Gastric Cancer in the @TheLancet covering the latest in the treatment and management of this illness @LizzySmyth1 @KoheiShitara @HannekevanLaar1 @MarkarSheraz @YJanjigianMD & Izuma Nakayama. thelancet.com/journals/lance…
Excited to share biomarker analysis of CM649 @NatureMedicine @YJanjigianMD Nivo benefit was enriched in TMB-H> EBV and GS > CIN. Targeted tx is needed for CIN. Nivo+Ipi benefit was seen in Treg↑ (FOXP3+CCR8), supporting Treg or CCR8 targeting tx in GC. nature.com/articles/s4159…
Mattehorn study showed EFS improvement and strong OS trend with FLOT+duravalumab. Great news to establish the global standard for fit patients with locally advanced gastric/GEJ cancer. Looking forward to the detail.@OncoAlert @oncodaily astrazeneca.com/media-centre/p…
DESTINY-Gastric04 demonstrated significantly prolonged OS with T-DXd vs. PTX+RAM in HER2+ gastric cancer. A major advancement for patients! Congratulations to all involved! @OncoAlert @oncodaily @DaiichiSankyoUS @AstraZeneca daiichisankyo.com/files/news/pre…
Pleased to share P2 results of futibatinib for FGFR2-amplified gastric cancer: ORR 17.9%. Shows some activity but underscores need for better options. Eagerly awaiting P3 chemo + bemarituzumab data @OncoAlert @myESMO @oncodaily ejcancer.com/article/S0959-…
LEAP15 for gastric cancer did not meet OS endpoint. Drop of chemo or dose of LEN/toxicities matter? Need learn from negative trial @OncoAlert @oncodaily merck.com/news/merck-and…
Excellent table to show all the current data of CAR-T therapy in GI cancers. Note that median PFS is not more than 3 to 6 months . And most of the trials have very small number of pts. By @KoheiShitara @ASCO #GI25 @Larvol